Phase 2 N=142 Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma
Sarcoma, Soft Tissue
Primary: Progression Free Survival at Week 12 — 0; 0; 0; 0 participants — p=0.653
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=230 The Use of Rotigotine for Treatment of Reducing Signs and Symptoms of Fibromyalgia in Adults.
Fibromyalgia Syndrome
Primary: Change From Baseline in Average Daily Pain Score to the Last 2 Weeks of the 12-week Treatment Phase (Based on the Full Analysis Set) — -1.12; -1.27; -0.83 Score on a scale
Phase 2 N=64 Gemcitabine or Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation in Non Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: 2-Year Survival — 40.6; 55.7 percentage of participants
Phase 2 N=397 A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
Overactive Bladder · Detrusor Overactivity
Primary: Change From Baseline in Bladder Volume at First Detrusor Contraction at 6 Weeks — 44.993; 36.948 mL — p=0.5293
Phase 2 N=62 Clinical Evaluation of Ropinirole PR/XR Tablets in Monotherapy for Parkinson's Disease (PD)
Parkinson Disease
Primary: Food Effects on Cmax and Cmin of SKF101468 (Ropinirole) and Its Metabolites — 1563.784; 1542.182; 728.404; 725.103 picograms/milliliter (pg/mL)
Phase 2 N=84 A Randomized Trial of Avastin + Gemcitabine + 5-Fluorouracil (5FU)/Folinic Acid Versus Avastin + Oxaliplatin + 5FU/Folinic Acid in Metastatic Colorectal Cancer
Colorectal Cancer
Primary: Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST) — 1; 2; 3; 15 participants
Phase 2 N=45 Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Discontinuations Due to Adverse Events (AE) — 1; 1 participants
Phase 2 N=61 SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Number of Subjects With Overall Confirmed Objective Disease Response According to the Response Evaluation Criteria in Solid Tumors (RECIST) — 14 participants
Phase 2 N=1,040 Human Papillomavirus (HPV) Vaccine (Cervarix TM) Efficacy, Immunogenicity & Safety Trial in Adult Japanese Women With GSK Biologicals HPV-16/18 Vaccine
Infections, Papillomavirus
Primary: Number of Subjects With Persistent Cervical Infection With Human Papillomavirus 16 (HPV-16) or Human Papillomavirus 18 (HPV-18) — 0; 15; 0; 11 Participants
Phase 2 N=115 Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America
Infections, Papillomavirus
Primary: Number of Subjects With Anti-human Papilloma Virus-16 (Anti-HPV-16) and Anti-HPV-18 Antibody Titers Greater Than or Equal to Pre-defined Cut-off Values — 61; 30; 57; 45…
Phase 2 N=11 A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
Peanut Hypersensitivity
Primary: Serious Adverse Events — 0; 1; 0; 1 participants
Phase 2 N=51 A Study of Aplidin (Plitidepsin) 3 h iv in Subjects With Relapsing or Refractory Multiple Myeloma
Multiple Myeloma
Primary: Objective Response Rate (ORR), Defined as the Combined Rate of Complete Response, Partial Response and Minimal Response — 0; 0; 3; 11 percentage patients
Phase 2 N=145 Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®
Meningitis · Meningococcal Infection
Primary: Participants With Serum Bactericidal Activity of ≥ 1:8 for Each Menactra® Vaccine Serogroups Pre-vaccination and 28 Days Post-booster or Post-primary Dose Vaccination…
Phase 2 N=62 GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
Neoplasms, Breast
Primary: Overall Tumor Response — 1; 8; 18; 29 participants
Phase 2 N=62 Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
Non Small Cell Lung Cancer
Primary: Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response) — 28.6 percentage of participants